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Abstract 
Peroxisomes and mitochondria in mammalian cells are closely linked subcellular organelles, 
which maintain a redox-sensitive relationship. Their interplay and role in ROS signalling is 
supposed to impact on age-related and degenerative disorders. Whereas the generation of 
peroxisome-derived oxidative stress can affect mitochondrial morphology and function, little 
is known about the impact of mitochondria-derived oxidative stress on peroxisomes. Here, we 
investigated the effect of the mitochondrial complex I inhibitor rotenone on peroxisomal and 
mitochondrial membrane dynamics. We show that rotenone treatment of COS-7 cells alters 
peroxisome morphology and distribution. However, this effect is related to its microtubule-
destabilising activity rather than to the generation of oxidative stress. Rotenone also induced 
alterations in mitochondrial morphology, which – in contrast to its effect on peroxisomes - 
were dependent on the generation of ROS but independent of its microtubule-active 
properties. The importance of our findings for the peroxisome-mitochondria redox 
relationship and the interpretation of in cellulo and in vivo studies with rotenone, which is 
widely used to study Parkinson’s disease, are discussed. 
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Introduction 
Peroxisomes are ubiquitous and dynamic single membrane-bound organelles in eukaryotic 
cells, that - similar to mitochondria - show an oxidative type of metabolism. Peroxisomes 
perform important functions in hydrogen peroxide and lipid metabolism rendering them 
essential for human health and development (Wanders and Waterham 2006). To fulfil their 
multiple functions, peroxisomes need to communicate and cooperate with other organelles, 
including mitochondria, the endoplasmic reticulum (ER) or lipid droplets (Schrader et al. 
2013; Schrader et al. 2015a; 2015b; Gao and Goodman 2015; Costello et al. 2017). Over the 
years, substantial evidence has been provided for a close functional interplay between 
peroxisomes and mitochondria (the so-called “peroxisome-mitochondria connection”) which 
impacts on human health and development (Schrader and Yoon 2007; Camoes et al. 2009; 
Schrader et al. 2015a). Peroxisomes and mitochondria in mammalian cells cooperate 
metabolically in the breakdown of fatty acids by β-oxidation (reviewed in Wanders et al. 
2016), they maintain a redox-sensitive relationship (reviewed in Lismont et al. 2015), share 
key components of the membrane fission machineries (reviewed in Schrader et al. 2012, 
2016), cooperate in anti-viral signalling (Dixit et al. 2010; Odendall et al. 2014) and may 
depend on each other for biogenesis and functionality (Peeters et al. 2011, 2015; Mohanty and 
McBride 2013; Sugiura et al. 2017). Of particular interest are their redox-sensitive 
relationship and their interplay and communication with respect to ROS signalling, which 
may impact on age-related and degenerative disorders (Koepke et al. 2008; Ivashchenko et al. 
2011; Walton and Pizzitelli, 2012; Titorenko and Terlecky 2011; Beach et al. 2012; Fransen 
et al. 2013; Nordgren and Fransen 2014). The generation of oxidative stress in peroxisomes 
has been shown to impact on mitochondrial morphology and function (Ivashchenko et al. 
2011; Wang et al. 2013). However, little is known about the impact of mitochondria-derived 
oxidative stress on peroxisomes. Here, we have examined the effect of the potent complex I 
inhibitor rotenone on peroxisomal and mitochondrial membrane dynamics. We show that 
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although rotenone has an impact on peroxisome morphology and distribution, this effect is 
related to its microtubule-destabilising activity rather than to oxidative stress. On the other 
hand, rotenone induced alterations in mitochondrial morphology, which were dependent on 
the generation of ROS but independent of its microtubule-active properties.  
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Materials and methods 
Antibodies 
Antibodies were used as follows: rabbit polyclonal antibody against PEX14 (1:1400, kindly 
provided by D. Crane, Griffith University, Brisbane, Australia) (Nguyen et al. 2006; Grant et 
al. 2013), mouse monoclonal antibodies against α-tubulin (Sigma, T9026) and acetylated α-
tubulin (Sigma, T6793) (both used at 1:200 for immunofluorescence, 1:1000 for 
immunoblotting), and TOM20 (1:200 for immunofluorescence) (BD Transduction 
Laboratories, San Diego, USA; 612278). Secondary anti-IgG antibodies against rabbit (Alexa 
488, 1:500; A21206) and mouse (Alexa 488, 1:400, A21202 and Alexa 594, 1:1000, A21203) 
were obtained from Molecular Probes (as part of Invitrogen Life Technologies, Eugene, 
USA). Anti-mouse IgG antibodies conjugated to HRP (1:5000, 170-6516) were obtained from 
Bio-Rad (Munich, Germany). The specificity of all antibodies has been validated in several 
previous studies.  
 
Cell culture and drug treatment 
COS-7 (African green monkey kidney cells; ATCC CRL-1651) were cultured in DMEM, 
high glucose (4.5 g/L) supplemented with 10% FBS, penicillin and streptomycin (all from 
Life Technologies) at 37°C with 5% CO2 and 95% humidity (HERACell 240i CO2 incubator). 
Cells were seeded onto glass coverslips (Fisher Scientific, 19 mm Ø, 0.13-0.17 mm thickness) 
at a defined density (1×105 cells/ml). 24 hours after seeding, the culture medium was 
aspirated, and cells were treated for different time intervals (3, 6 and 24 hours) with a range of 
concentrations of rotenone (Sigma, R8875) (100 nM, 1 µM, 10 µM, 100 µM, 1 mM). For pre-
treatment with the microtubule-stabilizing drug paclitaxel (taxol) (Sigma, T7402), cells were 
first incubated with 20 µM paclitaxel for 6 hours before the addition of rotenone. For pre-
treatment with the antioxidant N-acetyl cysteine (NAC) (Sigma, A7250), cells were first 
incubated with 10 mM NAC for 1 hour before the addition of rotenone. Stock concentrations 
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of 100 mM rotenone and 2 mM paclitaxel were prepared in dimethyl sulfoxide (DMSO) 
(Sigma, D8418) and dilutions prepared in culture medium. A stock concentration of 100 mM 
NAC was prepared always fresh in culture medium, and diluted in culture medium following 
pH neutralization and sterilization by filtration of the stock. 
 
Immunofluorescence and microscopy 
Cells grown on glass coverslips were washed twice with phosphate-buffered saline (PBS). 
Cells to be stained with organelle markers (e.g. PEX14 or TOM20) were fixed using 4% 
paraformaldehyde, pH 7.4 for 20 minutes at room temperature as previously described 
(Bonekamp et al. 2013) as peroxisome morphology is sensitive to alcoholic fixation (Schrader 
et al. 1995). Cells to be stained with cytoskeletal markers (e.g. α-tubulin or acetylated α-
tubulin) were fixed with ice-cold methanol for 15 minutes at -20°C. Following fixation cells 
were washed 3 times in PBS, membranes were permeabilised with 0.2% Triton X-100 for 10 
minutes at room temperature (permeabilisation was omitted for methanol-fixed cells), washed 
again 3 times in PBS and blocked with 2% bovine serum albumin (BSA) for 10 minutes at 
room temperature. Cells were then incubated for 1 hour with primary antibodies diluted in 
PBS, washed 3 times in PBS and incubated for 1 hour with secondary antibodies diluted in 
PBS. In controls, where the primary antibodies were omitted, no staining reactions were 
observed. To mount coverslips on slides, cells were washed 3 times in PBS, dipped in dH2O 
and mounted (after removal of excess water) in Mowiol 4-88 containing n-propyl galate as an 
anti-fading (Bonekamp et al. 2013). Cell imaging was performed using an Olympus IX81 
microscope with an UPlanSApo 100x/1.40 Oil objective (Olympus Optical, Hamburg, 
Germany), eGFP ET filter-set (470/40 Et Bandpass filter, Beamsplitter T495 LPXR and 
525/50 ET Bandpass filter (Chroma Technology GmbH, Olching, Germany)), TxRed HC 
Filter Set (562/40 BrightLine HC Beamsplitter HC BS 593, 624/40 BrightLine HC (Semrock, 
Rochester, USA)). Images were taken with a CoolSNAP HQ2 CCD camera (150-300 ms 
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exposure, gain 3, bin 1, gamma 1) and MetaMorph 7 (Molecular Devices, USA) was used to 
adjust for contrast and brightness.  
 
Gel electrophoresis and immunoblotting 
Following drug treatment, cells were trypsinised, washed in PBS and centrifuged at 500 ×g 
for 3 min. Cell pellets were lysed (25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% sodium 
deoxycholate, 1.5mM Triton X-100 and a protease-inhibitor mix (Roche Diagnostics)) and 
protein concentrations were determined using the Bradford assay (Bradford 1976) (Bio-Rad 
Protein Assay Dye Reagent Concentrate, 5000006). Equal amounts of protein were separated 
by SDS-PAGE on 12.5% polyacrylamide gels, transferred to nitrocellulose membrane 
(Amersham Bioscience, Arlington Heights, IL, USA) using a semi-dry apparatus (Trans-Blot 
SD, Biorad) and analysed by immunoblotting using the corresponding primary antibodies and 
horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence 
reagents (Amersham Bioscience, Arlington Heights, IL, USA).  
 
Measurement and quantification of ROS production 
Intracellular ROS levels were measured using the fluorescent dye 2′, 7′-
dichlorodihydrofluorescein diacetate (H2DCFDA) (Molecular Probes, Life Technologies). 
H2DCFDA is intracellularly oxidized by ROS, producing the fluorescent compound 
dichlorofluorescein (DCF), which can be detected by measuring the fluorescence at 530 nm 
when excited at 485 nm (Fernandez-Gomez et al. 2006; Perez-Ortiz et al. 2004). Cells were 
seeded in 96-well culture plates (104 cells/well) (Greiner Bio-One) and treated with rotenone 
after 24 hours. At different time points, the medium was removed and the cells were washed 
one time with PBS. Cells were incubated with 10 µM H2DCFDA and the fluorescence 
intensity was measured immediately every 5 minutes over a period of 30 minutes in a 
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multifunctional microplate reader (TECAN i-control – infinite 200, Austria GmbH). An 
average of 4 to 6 wells per condition was measured and a mean value obtained. Controls 
included untreated cells, a blank containing cell culture medium and dye; and H2O2 together 
with the dye as a positive control). A linear increase of fluorescence with time was plotted and 
used to calculate a linear regression. From this the average relative percentage of ROS 
production was determined from at least 3 independent experiments. 
 
Quantification and statistical analysis of data 
Analysis of statistical significance was performed using GraphPad Prism 5 software. A two-
tailed unpaired t-test was used to determine statistical difference against the indicated group. 
*p<0.05, **p<0.01, ***p<0.001. For analysis of organelle distribution and morphology, a 
minimum of 150 cells were examined per condition, and organelle parameters (e.g. tubular, 
elongated morphology, intracellular distribution/clustering) were microscopically assessed in 
at least 3 independent experiments. The analysis was made blind and in different areas of the 
coverslip. Data are presented as mean ± SD. 
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Results and Discussion 
Rotenone alters peroxisome morphology and distribution 
Rotenone, an agricultural pesticide, is well known to inhibit complex I (NADH CoQ1 
reductase) in the mitochondrial respiratory chain (Chance et al. 1963; Higgins and 
Greenamyre 1996). It is a widely used toxin employed in animal and cellular models of 
Parkinson’s disease and can freely cross cell membranes (Betarbet et al. 2000; Alam et al. 
2002; Mounsey and Teismann 2010). Chronic treatments with rotenone in mice reproduce 
some features of this disease such as motor deficits, protein aggregation, and loss of 
dopaminergic neurons (Meurers et al. 2009). Complex I inhibition has several potential 
functional consequences, including ATP depletion, which in turn induces oxidative stress in 
cells (Sherer et al. 2003; Testa et al. 2005). To examine whether an inhibitor of the 
mitochondrial respiratory chain known to produce ROS exhibits an effect on the peroxisomal 
compartment, COS-7 cells were treated with different concentrations of rotenone (100 nM, 1 
µM, 10 µM, 100 µM, 1 mM). Treated cells and controls were processed for 
immunofluorescence after 6 and 24 hours, and peroxisomes were labelled with antibodies 
against Pex14, a peroxisomal membrane protein (Fig. 1). Peroxisomes in COS-7 cells are 
uniformly distributed in the cytoplasm, and are usually spherical in shape (Fig. 1a) (Koch et 
al. 2004; Lin et al. 2016). Treatment with rotenone induced a concentration-dependent 
elongation of the peroxisomal compartment (Fig. 1b, e) as well as clustering of peroxisomes 
(Fig. 1c, f) and an uneven distribution of the organelles in the cytoplasm (Fig. 1d). Cells 
showed either tubular or clustered peroxisomes or a mixture of both. Peroxisome elongation is 
a pre-requisite of peroxisome multiplication by growth and division (Schrader et al. 2012; 
2016), and tubular peroxisomes can be induced by different stimuli including growth factors, 
fatty acids, and ROS (Schrader et al. 1998; 1999; Schrader and Fahimi 2006). However, 
peroxisome elongation, clustering and altered distribution has also been observed under 
conditions of microtubule-depolymerisation (Schrader et al. 1996; Wiemer et al. 1997), as 
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peroxisome motility and distribution depends on microtubules in mammalian cells (Schrader 
et al. 1996; 2003; Wiemer et al. 1997; Lin et al. 2016). Furthermore, rotenone has been 
reported to inhibit microtubule polymerization and to arrest cell cycle progression at mitosis 
(Meisner and Sorensen 1966; Brinkley et al. 1974; Marshall and Himes 1978; Srivastava and 
Panda 2007). We thus investigated microtubule integrity after treatment of COS-7 cells with 
rotenone. 
 
Rotenone exerts a microtubule-destabilising activity in COS-7 cells 
COS-7 cells were treated with different concentrations of rotenone and methanol-fixed. 
Controls and treated cells were stained with antibodies to α-tubulin (Fig. 2). In controls, 
microtubules form the typical radial arrays originating from the microtubule-organising centre 
(MTOC) in interphase cells (Fig. 2a). At low rotenone concentrations, microtubules were still 
visible and appeared unaffected (Fig. 2b, c). At an intermediate concentration of 10 µM, some 
microtubules remained, but the majority was depolymerised (Fig. 2d). Treatment with higher 
rotenone concentrations resulted in a complete depolymerisation of microtubules (Fig. 2e, f). 
The effect of rotenone on microtubules was similar after 3, 6 and 24 hours.  
To investigate microtubule integrity at low rotenone concentrations, microtubules were 
stained with an antibody to acetylated α-tubulin (Fig. 2g-i, j). Acetylated α-tubulin is present 
in various microtubule structures and plays a role in the stabilization of microtubules (Piperno 
et al. 1987). In control cells only a few microtubules were labelled per cell (Fig. 2g). 
Interestingly, cells treated with low concentrations of rotenone showed a prominent increase 
in microtubules containing acetylated α-tubulin (Fig. 2h, i). An increase in acetylated tubulin 
was confirmed by immunoblotting of cell lysates from controls and rotenone-treated cells 
(Fig. 2j). These findings indicate that although microtubules appear unaffected in cells treated 
with low concentrations of rotenone based on α-tubulin staining, they already display 
posttranslational modifications such as acetylation. Tubulin acetylation likely serves to 
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stabilise microtubules and to counteract the destabilising activity of rotenone. It has been 
suggested that rotenone inhibits microtubule assembly by binding to tubulin thus inducing a 
conformational change in tubulin (Srivastava and Panda 2007).  
 
Alterations in peroxisome distribution induced by rotenone are caused by microtubule 
depolymerisation  
To investigate if peroxisome alterations induced by rotenone are primarily caused by 
microtubule depolymerisation (or alternatively by Complex I inhibition and oxidative stress), 
we first pre-incubated COS-7 cells with the microtubule-stabilising agent paclitaxel prior to 
the addition of rotenone (Fig. 3). Paclitaxel, which causes the formation of microtubule 
bundles (Fig. 3a, b) protected the microtubules against the microtubule-depolymerising 
activity of rotenone, even when high concentrations of rotenone were applied (Fig. 3c, d). 
Interestingly, addition of rotenone after the stabilization of microtubules with paclitaxel 
showed no effect on peroxisomes (Fig. 3g-i). Peroxisome distribution was mostly uniform, 
and clustering was similar to the paclitaxel-treated control (Fig. 3g-i). It should be noted that 
paclitaxel alone increased cluster formation in COS-7 cells when compared to untreated 
controls, but this was mainly due to fragmentation of the nucleus, which affected the uniform 
distribution of peroxisomes in the cytoplasm (Fig. 3b, f). As peroxisome elongation is 
influenced by many factors (e.g. culture condition, cell density) (Schrader et al. 1996; 
Schrader and Fahimi 2006), we focussed on the analysis of peroxisomal distribution. 
However, rotenone-induced peroxisome elongation was no longer observed after pre-
treatment with paclitaxel (Fig. 3g, h) and not different from controls (Fig. 3e, f) (unpublished 
observation). Our findings are in line with previous findings showing that paclitaxel provides 
protective effects against rotenone-induced toxicity (Jiang et al. 2006). Moreover, paclitaxel 
had no effect on the morphology and distribution of peroxisomes in HepG2 cells, but pre-
treatment with paclitaxel and stabilization of microtubules prevented alterations of 
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peroxisome morphology and distribution caused by microtubule-depolymerising agents such 
as nocodazole (Schrader et al. 1996). The results show that the effect of rotenone on 
peroxisomes in mammalian cells is similar to the action of the microtubule-depolymerising 
drugs nocodazole, colcemid and vinblastine (Schrader et al. 1996). We suggest that 
peroxisome alterations in mammalian cells induced by rotenone are mainly caused by the 
microtubule-destabilising activity of rotenone rather than via complex I inhibition and 
oxidative stress.  
 
Rotenone-induced intracellular ROS are not the major cause of peroxisome alterations 
in COS-7 cells 
Rotenone interferes with the mitochondrial electron transport chain, by inhibiting the transfer 
of electrons from iron-sulphur centres in complex I to ubiquinone. This prevents NADH from 
being converted into usable cellular energy (ATP) and consequently leads to ROS production. 
To examine if peroxisome alterations are a consequence of rotenone-dependent ROS 
production, intracellular ROS levels were measured in COS-7 cells under control conditions 
and after treatment with 100 nM rotenone (a concentration not affecting microtubule 
integrity) using 2′7′-dichlorodihydrofluorescein diacetate (H2DCFDA) which is intracellularly 
oxidized by ROS, producing the fluorescent compound dichlorofluorescein (DCF). As shown 
in Fig. 4a, rotenone increases intracellular ROS levels in COS-7 cells after 6 hours (276 ± 
6%) and 24 hours (414 ± 18%) when compared to control conditions. Furthermore, pre-
treatment of COS-7 cells with the antioxidant N-acetyl cysteine (NAC) prior to the addition of 
rotenone reduced intracellular ROS levels (Fig. 4a). These findings are in line with published 
results (Bonet-Ponce et al. 2016). More importantly, pre-treatment with NAC prior to the 
addition of rotenone did not prevent clustering of peroxisomes and changes in the uniform 
distribution of the organelle (Fig. 4b). NAC alone only induced a slight increase in 
peroxisomal clusters compared to control conditions. These observations support our 
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assumption that peroxisome alterations in mammalian cells induced by rotenone are mainly 
caused by the microtubule-destabilising activity of rotenone and not via complex I inhibition 
and increased intracellular ROS levels. 
 
Rotenone alters mitochondrial morphology in a ROS dependent manner 
Next, we investigated the morphology of mitochondria in COS-7 cells treated with different 
concentrations of rotenone. Treated cells and controls were processed for 
immunofluorescence, and mitochondria were labelled with antibodies against TOM20, a 
mitochondrial outer membrane protein (Fig. 5). Mitochondria in COS-7 cells usually display 
an elongated, tubular and bulbous morphology (Fig. 5a, e, i) (Koch et al. 2004). In contrast to 
its elongating effect on peroxisomes (Fig. 1), rotenone induced a concentration-and time-
dependent fragmentation of mitochondria resulting in a spherical, round organelle phenotype 
(Fig. 5b, c, d). Pre-treatment of COS-7 cells with paclitaxel to stabilise microtubules did not 
prevent mitochondrial fragmentation (Fig. 5e-h). However, pre-treatment of COS-7 cells with 
the antioxidant NAC prevented mitochondrial fragmentation even at high rotenone 
concentrations and maintained a tubular mitochondrial morphology (Fig. 5i-l). These findings 
indicate that mitochondrial alterations in mammalian cells induced by rotenone are mainly 
caused by complex I inhibition and increased intracellular ROS levels rather than via the 
microtubule-destabilising activity of rotenone, which is in contrast to its action on 
peroxisomes. 
We conclude from these observations that at low concentrations (100 nM -10 µM) rotenone 
acts on mitochondria in COS-7 cells and induces their fragmentation, likely due to inhibition 
of complex I and subsequent oxidative stress/increased intracellular ROS levels. Microtubules 
at these concentrations are still intact (Fig. 2), although exhibiting increased levels of 
acetylated α-tubulin (Fig. 2). Alterations in peroxisome morphology and distribution are more 
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prominent at higher rotenone concentrations, as they are induced by the microtubule-
depolymerising activity of rotenone, and not primarily via increased intracellular ROS levels.  
Our findings support published data indicating that mitochondria are more susceptible to 
changes in cellular redox homeostasis and increased ROS levels than peroxisomes. For 
example, the neurotoxin 6-Hydroxydopamine, which is supposed to cause ROS generation 
(Galindo et al. 2003), induced a profound mitochondrial fragmentation in SH-SY5Y 
neuroblastoma cells, but failed to induce any changes in peroxisome morphology (Gomez-
Lazaro et al. 2008). In line with this, we observed no effect on peroxisome morphology when 
other inhibitors of mitochondrial respiration were used (e.g. sodium azide, an inhibitor of 
cytochrome c oxidase/complex IV) (unpublished observations). Furthermore, peroxisomes 
were found to resist oxidative stress generated elsewhere in the cell, whereas generation of 
excess ROS inside peroxisomes perturbed the mitochondrial redox balance and led to 
mitochondrial fragmentation and cell death (Ivashchenko et al. 2011; Wang et al. 2013). How 
redox communication between peroxisomes and mitochondria is mediated, is currently 
unclear, but may involve a more complex signalling system as opposed to simple diffusion of 
excess ROS (Lismont et al. 2015).  
Our data also indicate that in cellulo and in vivo studies with rotenone, which has been widely 
used to study Parkinson’s disease (Betarbet et al. 2000), have to be carefully interpreted due 
to the different effects of rotenone in mammalian cells. We show that besides increasing 
intracellular ROS levels, mitochondrial fragmentation, and microtubule depolymerisation, 
rotenone also has an effect on peroxisome dynamics and distribution. Such processes are 
important for the formation of peroxisomes by growth and division, their intracellular 
positioning, movement and interaction with other subcellular compartments and have been 
linked to human health and disease (Schrader et al. 2015a; Ribeiro et al. 2012). Mitochondrial 
dysfunction is commonly accepted as having a key role in Parkinson’s disease, however, 
microtubule alterations are also considered. For example, 1-methyl-4-phenyl-1,2,3,6-
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tetrahydropyridine (MPTP), another model toxin for Parkinson’s disease, impacts on 
microtubule polymerization besides its effect on mitochondria (Cartelli et al. 2010). 
Disrupting the microtubule network can alter vesicular and organelle transport in neurons 
leading to neuronal death (Ren et al. 2005; De Vos et al. 2008; Cartelli et al. 2010). Loss of 
peroxisome dynamics and distribution may contribute to this process. 
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Figure legends 
Fig. 1 Rotenone induces alterations in peroxisome morphology and distribution. COS-7 cells 
were treated with solvent (CON) or rotenone (ROT) for 6 and 24 hours and processed for 
immunofluorescence microscopy using antibodies directed to PEX14, a peroxisomal 
membrane protein. (a-d) Representative examples. (a) Control (CON). Note the elongated 
tubular peroxisomes in (b) (1 mM ROT, 6 hours), the formation of peroxisomal clusters (c, 
arrowheads) (100 µM ROT, 6 hours), and the non-uniform distribution of peroxisomes (d) 
(100 µM ROT, 6 hours) in contrast to (a). Boxed region in (b) shows higher magnification 
view. (e, f) Qualitative assessment of peroxisome elongation (e) and cluster formation (f). A 
minimum of 150 cells were examined per condition, and organelle morphology and 
distribution was microscopically assessed. Values represent mean ± SD of at least 3 
independent experiments. N, nucleus. Bar, 10 µm.  
 
Fig. 2 Rotenone induces microtubule depolymerisation and acetylation of α-tubulin in COS-7 
cells. (a-f) Cells were treated with solvent (a) (CON) or different concentrations of rotenone 
(ROT) (b-f) for 6 hours and processed for immunofluorescence microscopy using antibodies 
directed to α-tubulin. (g-i) Cells were treated with solvent (g) (CON), 100 nM rotenone (h) or 
1 µM rotenone (i) for 3 hours and labelled with antibodies directed to acetylated α-tubulin. (j) 
Immunoblot of cell lysates showing levels of acetylated α-tubulin after 3 hours of rotenone 
treatment. 50 µg of protein were loaded and the blot probed with acetylated α-tubulin and α-
tubulin antibody as indicated. α-tubulin serves as loading control. Bars, 10 µm. 
 
Fig. 3 Microtubule stabilisation prevents rotenone-induced clustering of peroxisomes. COS-7 
cells were treated with solvent (CON) (a, e), paclitaxel (TAX) (b, f), paclitaxel and 100 µM 
rotenone (ROT) (c, g), or paclitaxel and 1 mM rotenone (d, h) for 6 and 24 hours. Cells were 
then processed for immunofluorescence microscopy using antibodies directed to α-tubulin (a-
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d) or PEX14 (e-h). (i) Qualitative assessment of peroxisome cluster formation. A minimum of 
150 cells were examined per condition, and organelle distribution was microscopically 
assessed. Values represent mean ± SD of at least 3 independent experiments. P-values refer to 
appropriate controls unless indicated. Bar, 10 µm. 
 
Fig. 4 Antioxidant treatment reduces rotenone-induced intracellular ROS levels, but does not 
prevent peroxisomal clustering. (a) Determination of intracellular ROS levels using the 
fluorescent dye 2′, 7′-dichlorodihydrofluorescein diacetate (H2DCFDA) after treatment of 
COS-7 cells with the antioxidant N-acetyl cysteine (NAC), 100 nM rotenone (ROT), or N-
acetyl cysteine and 100 nM rotenone. Data are expressed as percentage of control (mean ± 
SD) and are from 3 independent experiments. (b) Qualitative assessment of peroxisome 
cluster formation (as described for Fig. 3). Cells were treated as indicated and processed for 
immunofluorescence microscopy using antibodies directed to PEX14. Values represent mean 
± SEM of at least 3 independent experiments. P-values refer to appropriate controls unless 
indicated. 
 
Fig. 5 Rotenone-induced mitochondrial fragmentation can be prevented by antioxidant-
treatment but not by microtubule stabilization. (a-d) Rotenone induces the formation of 
spherical mitochondria. COS-7 cells were treated with solvent (CON) (a) or rotenone (ROT) 
for 6 (b, c, d) and 24 hours (d) and processed for immunofluorescence microscopy using 
antibodies directed to TOM20, a mitochondrial outer membrane protein. Note the elongated 
tubular mitochondria in (a) in contrast to (b, c). (d) Qualitative assessment of mitochondrial 
morphology. A minimum of 150 cells were examined per condition, and organelle 
morphology was microscopically assessed. Values represent mean ± SD of at least 3 
independent experiments. (e-h) Microtubule stabilisation does not prevent rotenone-induced 
mitochondrial fragmentation. COS-7 cells were treated with paclitaxel (TAX) (e) or paclitaxel 
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and rotenone (ROT) for 6 (f, g, h) and 24 hours (h) and labelled with TOM20 antibodies. 
Note the elongated tubular mitochondria in (e) in contrast to (f, g). (h) Qualitative assessment 
of mitochondrial morphology (see above). (i-l) Antioxidant-treatment prevents rotenone-
induced mitochondrial fragmentation. COS-7 cells were treated with N-acetyl cysteine (NAC) 
(i) or N-acetyl cysteine and rotenone (ROT) for 3 (j, k, l) and 6 hours (l) and labelled with 
TOM20 antibodies. Note the elongated tubular mitochondria in (j, k, l) in contrast to (b, c, f, 
g). (l) Qualitative assessment of mitochondrial morphology (see above). P-values refer to 
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Fig. 5 
